Abstract 2749
Background
With the expanding use of CPI in different types of cancer, we have been challenged with the lack of safety and efficacy data of CPI post allogeneic stem cell therapy (SCT).
Methods
We systematically reviewed our institutional databases through March 2018 and identified patients (pts) who received CPI for treatment of cancer after allogeneic SCT. In addition, we systematically reviewed the literature through August 2018 to identify studies reporting use of CPIs post-allogeneic SCT. We evaluated the prevalence of graft vs host disease (GVHD), immune-related adverse events (irAEs), tumor response, and mortality after CPI.
Results
A total of 38 pts were identified (10 from institutional databases & 28 from literature). The median age was 37.5 years (range 10–68 yrs). The most commonly used CPI was anti-PD1 84 %. Cancer types included hematologic malignancies (n = 36); primarily Hodgkin lymphoma in 58%, and solid tumors (n = 2). Median time to CPI initiation post SCT was 1.6 years (range 0.92–32 yrs). More than half of pts (59 %) were maintained on immunosuppressive agents: brentuximab vedotin, cyclophosphamide, and low dose prednisone at CPI initiation. GVHD occurred in 34.2 % (n = 13); nine were specified having acute GVHD (82%). The median time from initiation of CPI to GVHD was 14 days (range 5-21 days). In most pts, GVH was treated with steroids. Two thirds of pts achieved complete or partial tumor remission (ORR 66%), while 28% had disease progression. In pts who developed GVHD the ORR was 91.2%. Interestingly, of the 25 pts who were reported to have no GVHD, 10 had irAEs. There were total of 34% of death (n = 13), including 5% only (n = 2) were attributed to GVHD, while the remaining were secondary to either progression of disease, CPI irAE’s (Pneumonitis, Myocarditis), and other causes.
Conclusions
The use of CPI post-SCT has a significant anti-tumor response, but it was associated with an increased risk of acute GVHD. Prospective studies in this population (CPI post-SCT) with longitudinal on treatment biopsies are needed to understand the differences between allo-immunity, tumor immunity and auto-immunity (irAE).
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Adi Diab.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2664 - Phase (Ph) II study of MBG453 + spartalizumab in patients (pts) with non-small cell lung cancer (NSCLC) and melanoma pretreated with anti–PD-1/L1 therapy
Presenter: Nicholas Mach
Session: Poster Display session 3
Resources:
Abstract
1285 - Preliminary results of STELLAR-001, a dose escalation phase I study of the anti-C5aR, IPH5401, in combination with durvalumab in advanced solid tumors.
Presenter: Christophe Massard
Session: Poster Display session 3
Resources:
Abstract
3808 - GOLFIG chemo-immunotherapy in metastatic colorectal cancer (mCRC) patients: A fifteen year retrospective analysis
Presenter: Pierpaolo Correale
Session: Poster Display session 3
Resources:
Abstract
5677 - Immune correlates in peripheral blood samples in a preoperative window of opportunity randomized trial of nivolumab with or without tadalafil in resectable squamous cell carcinoma of the head and neck (SCCHN)
Presenter: Larry Harshyne
Session: Poster Display session 3
Resources:
Abstract
4854 - Phase 1 evaluation of AB928, a novel dual adenosine receptor antagonist, combined with chemotherapy or AB122 (anti-PD-1) in patients (pts) with advanced malignancies
Presenter: John Powderly
Session: Poster Display session 3
Resources:
Abstract
4344 - Phase 1 Trial of CV301 in Combination with Anti-PD-1 Therapy in Non-squamous NSCLC
Presenter: Arun Rajan
Session: Poster Display session 3
Resources:
Abstract
4555 - Safety and efficacy results of the combination of DPX-Survivac, pembrolizumab and intermittent low dose cyclophosphamide (CPA) in subjects with advanced and metastatic solid tumors: preliminary results from the hepatocellular carcinoma (HCC), NSCLC, bladder cancer, & MSI-H cohorts
Presenter: Henry Conter
Session: Poster Display session 3
Resources:
Abstract
3012 - Excellent CBR and Prolonged PFS in Non-Squamous NSCLC with Oral CA-170, an Inhibitor of VISTA and PD-L1
Presenter: Vivek Radhakrishnan
Session: Poster Display session 3
Resources:
Abstract
2536 - Phase Ib/II trial of TG4001 (Tipapkinogene sovacivec), a therapeutic HPV-vaccine, and Avelumab in patients with recurrent/metastatic (R/M) HPV-16+ cancers
Presenter: Christophe Le Tourneau
Session: Poster Display session 3
Resources:
Abstract
1845 - Induction of tumor-infiltrating functional CD8 positive cells and PD-L1 expression in esophageal cancer by S-588410
Presenter: Takashi Kojima
Session: Poster Display session 3
Resources:
Abstract